Search Results

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma’s New Drug Application (NDA) for Dasynoc ® , following a Complete Response Letter (CRL) where additional information was requested.

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announced today the online publication of its abstract titled “Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability” for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3rd, 2024 at 9-12 AM, Poster nr. 120 (1).

Xspray Pharma AB announced that XS003, its amorphous, non-crystalline formulation of nilotinib, has demonstrated bioavailability within the 80-125% range to TASIGNA® following oral administration with significantly lower dose.

Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CID-078, a first-and-only-in-class cyclin A/B RxL inhibitor.

Vicore Pharma Holding The shareholders of Vicore Pharma Holding AB, Reg. No. 556680-3804, with its registered offices in Stockholm, are summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden.

Promore Pharma AB intends to acquire all the shares in PMD Device Solutions AB by making payment in the form of newly issued shares in the Company.

Promore Pharma Promore Pharma AB, under change of name to PMD Device Solutions AB, held an extraordinary general meeting on Friday, 29 December 2023.